Tufts University’s School of Medicine and Sackler School of Graduate Biomedical Sciences and the British-Swedish pharmaceutical company AstraZeneca are currently in collaboration as part of a three-year agreement to perform cutting-edge research into biological targets in the field of neuroscience. As part of the agreement, AstraZeneca is working with Tufts to establish a team of postdoctoral researchers that will explore a variety of neurological pathways implicated in brain disease. Stephen Moss, Ph.D., serves as principal investigator and oversees the research.
Moss Laboratories is part of the Tufts University Neuroscience department. Tufts Neuroscience is dedicated to investigating the mechanisms of neurobiological disorders to improve therapeutic approaches to treating mental health. The department has a specific focus on drug development and discovering new drug targets for preclinical research.
Research at Moss Laboratories focuses on the receptors that mediate the actions of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the vertebrate nervous system. GABA receptors are also critical drug targets for anti-convulsants, sedatives and anesthetics. We are interested in understanding how neurons regulate the accumulation of these critical inhibitory receptors on the neuronal surface in addition to their functional properties. Given that altered GABA receptor function plays critical roles in a number of neuropsychiatric disorders, the results may lead to new insights and therapeutic strategies for such debilitating disorders as epilepsy, anxiety, schizophrenia, depression and substance abuse.